HeartBeam (BEAT) and Its Competitors Head to Head Analysis

HeartBeam (NASDAQ:BEAT) is one of 58 publicly-traded companies in the “MEDICAL INFO SYS” industry, but how does it compare to its peers? We will compare HeartBeam to similar companies based on the strength of its analyst recommendations, institutional ownership, profitability, risk, valuation, dividends and earnings.

Profitability

This table compares HeartBeam and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-571.06%	-353.09%
HeartBeam Competitors	-507.82%	-115.25%	-26.83%

Valuation & Earnings

This table compares HeartBeam and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
HeartBeam	N/A	-$21.01 million	-1.85
HeartBeam Competitors	$498.28 million	-$52.82 million	23.25

HeartBeam’s peers have higher revenue, but lower earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 43.7% of shares of all “MEDICAL INFO SYS” companies are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 17.1% of shares of all “MEDICAL INFO SYS” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

HeartBeam has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, HeartBeam’s peers have a beta of 2.09, indicating that their average share price is 109% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for HeartBeam and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1	1	5	1	2.75
HeartBeam Competitors	633	1011	2213	50	2.43

HeartBeam presently has a consensus target price of $4.80, indicating a potential upside of 317.39%. As a group, “MEDICAL INFO SYS” companies have a potential upside of 89.31%. Given HeartBeam’s stronger consensus rating and higher probable upside, equities research analysts clearly believe HeartBeam is more favorable than its peers.

Summary

HeartBeam beats its peers on 7 of the 13 factors compared.

HeartBeam Company Profile

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.